An Indian company has plans to begin commercial production of a sweetener to rival Tate & Lyle’s sucralose brand Splenda in 14 months, according to a report today.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Pharmed Medicare president Sundeep Aurora told Dow Jones newswires that the company is currently making trial products. The plan is to produce 1,000 tonnes of the sweetener in its first phase in just over a year’s time.
He added that Pharmed is in talks with several possible customers globally.